Bo Gao

7.7k total citations
70 papers, 1.2k citations indexed

About

Bo Gao is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Bo Gao has authored 70 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Oncology, 14 papers in Pulmonary and Respiratory Medicine and 13 papers in Molecular Biology. Recurrent topics in Bo Gao's work include Neurological Complications and Syndromes (9 papers), Moyamoya disease diagnosis and treatment (8 papers) and Cardiac Valve Diseases and Treatments (6 papers). Bo Gao is often cited by papers focused on Neurological Complications and Syndromes (9 papers), Moyamoya disease diagnosis and treatment (8 papers) and Cardiac Valve Diseases and Treatments (6 papers). Bo Gao collaborates with scholars based in China, United States and Canada. Bo Gao's co-authors include Alexander Lerner, Shenghong Ju, Yu‐Chen Chen, David M. Brown, Oliver Zeitz, René Rückert, Alyson J. Berliner, Quan Dong Nguyen, Robert Vitti and David S. Boyer and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Bo Gao

61 papers receiving 1.2k citations

Peers

Countries citing papers authored by Bo Gao

Since Specialization

Citations

This map shows the geographic impact of Bo Gao's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Bo Gao with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Bo Gao more than expected).

Fields of papers citing papers by Bo Gao

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Bo Gao. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Bo Gao. The network helps show where Bo Gao may publish in the future.

Co-authorship network of co-authors of Bo Gao

This figure shows the co-authorship network connecting the top 25 collaborators of Bo Gao. A scholar is included among the top collaborators of Bo Gao based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Bo Gao. Bo Gao is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	PcPreT-Net: Predicting classification of decline rate in prostate-specific antigen using graph neural network 2025 ·Displays ·(unknown), Feng Liu, Ying Cao, (unknown), (unknown), Wuchao Li, (unknown), (unknown), Yi Chen, Zhicheng Li, Yuanshen Zhao, Bo Gao, Rongpin Wang	0
2	Ocean ambient noise in the continental slope region of the northern South China sea 2025 ·Ocean Engineering ·Bo Gao, (unknown), (unknown), (unknown)	0
3	A critical review of biochar-enhanced Feammox: Multilevel mechanisms and sustainable applications for nitrogen removal 2025 ·Journal of environmental chemical engineering ·(unknown), Xiaonong Zhang, Ruiqin Zhao, (unknown), Bo Gao, (unknown)	0
4	A critical review of Mnammox coupled with the NDMO for innovative nitrogen removal 2024 ·The Science of The Total Environment ·(unknown), Xiaonong Zhang, Bo Gao, (unknown), Ruiqin Zhao, (unknown)	7
5	675P Evaluation of the safety and efficacy of JSKN003 in patients with advanced HER2-positive (IHC 3+) solid tumors (excluding breast cancer) 2024 ·Annals of Oncology ·(unknown), Dong Liu, (unknown), Zhijun Zhao, Bo Gao, Bin Liu, Jing Wu, Jing Zhang, Hong Zong, Jian Ruan, (unknown), (unknown)	1
6	Identifying pathological groups from MRI in prostate cancer using graph representation learning 2024 ·Displays ·Feng Liu, Yuanshen Zhao, (unknown), Jingxian Duan, Lei Tang, Bo Gao, Rongpin Wang	4
7	Long non‐coding RNA CASC15 enhances learning and memory in mice by promoting synaptic plasticity in hippocampal neurons 2024 ·SHILAP Revista de lepidopterología ·(unknown), Bo Gao, (unknown), Keying Zhang, (unknown), (unknown), Michael Aschner, Jingyuan Chen, (unknown), Lei Wang, Jianbin Zhang	7
8	Galunisertib promotes bevacizumab-induced vascular normalization in nasopharyngeal carcinoma: Multi-parameter MRI evaluation 2024 ·SHILAP Revista de lepidopterología ·(unknown), (unknown), Shuai Zhang, Jinhua Long, Peng Wu, (unknown), (unknown), Hong Qin, Pengyu Chen, Bo Gao	3
9	Artificial intelligence in medical imaging 2024 ·SHILAP Revista de lepidopterología ·(unknown), Bo Gao	1
10	Causal Associations of Air Pollution With Cardiovascular Disease and Respiratory Diseases Among Elder Diabetic Patients 2023 ·GeoHealth ·Zhiwei Li, Shiyun Lv, Feng Lü, Moning Guo, Zhiyuan Wu, Yue Liu, Weiming Li, Mengmeng Liu, Siqi Yu, (unknown), Bo Gao, Xiaonan Wang, Xia Li, Wei Wang, Xiangtong Liu, Xiuhua Guo	5
11	Yunvjian Improves Glucose and Insulin Function in Diabetic Rats by Regulating Gastric Emptying Function 2023 ·Evidence-based Complementary and Alternative Medicine ·(unknown), Lin Gao, Dandan Zhao, Lin Zhang, Bo Gao, (unknown), Guangtong Dong, Junping Wei	5
12	How and where the mitral valve leaks in functional mitral regurgitation 2019 ·SHILAP Revista de lepidopterología ·(unknown), Bo Gao, (unknown), Stephanie Wang, (unknown), Zhaoming He	2
13	P3.04-26 EMPOWER-Lung 4: A Phase 2 Study of Cemiplimab Plus Ipilimumab in the Second-Line Treatment of Advanced NSCLC with PD-L1 <50% 2018 ·Journal of Thoracic Oncology ·Naiyer A. Rizvi, (unknown), (unknown), (unknown), Bo Gao, Petra Rietschel	0
14	P3.04-24 EMPOWER-Lung 2: Cemiplimab and Ipilimumab ± Chemotherapy vs Pembrolizumab in Advanced NSCLC with PD-L1 ≥50%, a Phase 3 Study 2018 ·Journal of Thoracic Oncology ·Naiyer A. Rizvi, (unknown), (unknown), (unknown), Bo Gao, Petra Rietschel	1
15	P3.04-25 EMPOWER-Lung 3: A Phase 3 Study of Cemiplimab, Ipilimumab and Chemotherapy in Advanced NSCLC with PD-L1 <50% 2018 ·Journal of Thoracic Oncology ·Naiyer A. Rizvi, (unknown), (unknown), (unknown), Bo Gao, Petra Rietschel	2
16	Effect of polymorphisms in interleukin-18 gene on the susceptibility to coronary artery disease in a Chinese population 2016 ·Genetics and Molecular Research ·(unknown), (unknown), Bo Gao, Jianqiang Xu	8
17	A Phase I First-in-Human Study of Nesvacumab (REGN910), a Fully Human Anti–Angiopoietin-2 (Ang2) Monoclonal Antibody, in Patients with Advanced Solid Tumors 2015 ·Clinical Cancer Research ·Kyriakos P. Papadopoulos, Robin Kate Kelley, Anthony W. Tolcher, Albiruni R. Abdul Razak, Katherine Van Loon, Amita Patnaik, Philippe L. Bédard, (unknown), Muralidhar Beeram, Lieve Adriaens, Carrie Brownstein, Israel Lowy, Ana Kostić, Pamela A. Trail, Bo Gao, A. Thomas DiCioccio, Lillian L. Siu	59
18	Cytotoxic Edema in Posterior Reversible Encephalopathy Syndrome: Correlation of MRI Features with Serum Albumin Levels 2015 ·American Journal of Neuroradiology ·Bo Gao, (unknown), (unknown), (unknown), Haizhu Xie, (unknown), Chen Lv	28
19	Synergetic Effect of SLN-Curcumin and LDH-5-Fu on SMMC-7721 Liver Cancer Cell Line 2013 ·Cancer Biotherapy and Radiopharmaceuticals ·Rongrong Zhu, Xianzheng Wu, Yu Xiao, Bo Gao, Qian Xie, Hui Liu, Shilong Wang	29
20	A phase II multicentre study of ziv-aflibercept in combination with cisplatin and pemetrexed in patients with previously untreated advanced/metastatic non-squamous non-small cell lung cancer 2013 ·British Journal of Cancer ·(unknown), Manuel Modiano, Joel W. Neal, Julie R. Brahmer, James R. Rigas, Robert M. Jotte, Natasha B. Leighl, Jonathan W. Riess, Calvin J. Kuo, (unknown), Bo Gao, A. Thomas DiCioccio, Alex A. Adjei, Heather A. Wakelee	21

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact